Sage Therapeutics (NASDAQ:SAGE) traded lower for the third straight session on Tuesday after Bank of America moved the ...

As Sage Therapeutics Inc. contemplates its path forward after rejecting a buyout offer from Biogen, its top executive ...

Last year, the first phase 3 trial of Sage Therapeutics and Biogen's antidepressant hopeful zuranolone hit its efficacy targets, but raised doubts about the durability of the response. Now ...

Cambridge-based biopharmaceutical company Sage Therapeutics filed a lawsuit against their partner, the biotechnology company Biogen, after rejecting their $469 million buy-out proposal late last ...

Sage Therapeutics SAGE announced that its board of directors has rejected the unsolicited, non-binding proposal offer from drug giant Biogen BIIB to acquire the remaining shares of SAGE.

Sage Therapeutics and Biogen's antidepressant candidate zuranolone has hit its objectives in a phase 3 trial, but a falloff in efficacy over time has raised concerns about the commercial potential ...

BofA resumed coverage of Sage Therapeutics (SAGE) with an Underperform rating and $5 price target. The impact of Biogen’s (BIIB) unsolicited ...

Today, Benzinga 's options scanner spotted 32 uncommon options trades for Biogen. This isn't normal. The overall sentiment of these big-money traders is split between 37% bullish and 31%, bearish. Out ...

Biogen's strategic missteps, including the failed Sage Therapeutics acquisition, underscore a lack of innovation and direction, leading to a "sell" rating. Despite being forewarned, Wall Street ...

The reimbursement from Biogen to Sage for R&D expenses pursuant to the Sage/Biogen Collaboration and License Agreement was $1.3 million in the fourth quarter of 2024 compared to $8.3 million in ...